Your session is about to expire
← Back to Search
Palbociclib + Endocrine Therapy for Breast Cancer
Study Summary
This trial is testing whether a combination of endocrine therapy and the drug palbociclib is better than endocrine therapy alone as a treatment for hormone receptor positive breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My breast cancer is not Stage IV.You have had allergic reactions to drugs similar to palbociclib.I am not pregnant or have a recent negative pregnancy test.I am not on any hormone therapy.My HER2 test results are unclear.I am not taking strong medication that affects liver enzymes.I do not have any uncontrolled illnesses that would affect my participation.I have no cancer history, except for certain allowed conditions.I am taking medication for bone thinning while on this study.My breast cancer is at Stage I to III and the tumor is at least 1.5 cm big.The breast imaging should also include images of the armpit on the same side.Women who could still have children need to have a negative pregnancy test within a week before joining the study.I have been treated with a CDK inhibitor before.My breast cancer is confirmed as invasive lobular or ductal carcinoma.Your lab test results must be within certain limits.I agree to use birth control during and for 6 months after my treatment.I am postmenopausal, having had no periods for at least a year or have had both ovaries removed.I am not on HIV medication.I haven't had hormone therapy in the last 5 years before my current cancer diagnosis.I am fully active or can carry out light work.I have had DCIS in either the same or the opposite breast.My breast cancer is hormone receptor positive and HER2 negative.I am a woman aged 18 or older.I agree to have the necessary research biopsies before and after two weeks of endocrine therapy.
- Group 1: Arm B Letrozole Followed By Endocrine Therapy
- Group 2: Tamoxifen Followed By Endocrine Therapy and Palbociclib
- Group 3: Letrozole Followed By Endocrine Therapy and Palbociclib
- Group 4: Arm A Tamoxifen followed by Endocrine Therapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is participation in this clinical research experiment available to individuals at present?
"Unfortunately, this clinical trial is not presently accepting patients. It was first listed on May 24th 2016 and its last update was July 15th 2022. Nonetheless, 2883 other trials are currently open for recruitment."
To what maladies is Palbociclib commonly administered?
"Palbociclib is a therapeutic agent recommended to treat breast cancer, as well as post-surgery care, estrogen receptors, and other related issues."
To what extent is this medical trial being utilized by participants?
"This research endeavour is no longer accepting patients. It was initially posted on May 24th 2016 and the records were most recently updated on July 15th 2022. Individuals looking for other trials can peruse 2596 clinical studies recruiting breast cancer patients, with 287 of those focused specifically on Palbociclib."
Are there any existing research projects concerning Palbociclib?
"Palbociclib was initially researched at Queen Mary Univerity of London in 1994 and since then has been subject to 357 trials. Of the 287 active studies, a significant proportion is being conducted from Brewer, Maine."
Has the FDA sanctioned Palbociclib for therapeutic utilization?
"The safety of Palbociclib is estimated at level 2 on a 1-3 scale due to the presence of limited safety data and no clinical proof for its efficacy."
Share this study with friends
Copy Link
Messenger